PolyPeptide Reports Strong Profitability and Growth Amid Strategic Expansion

PolyPeptide Group AG has posted its annual results for 2024, exhibiting notable financial improvements. The company saw a revenue increase of 5.1% to EUR 336.8 million compared to 2023, driven by rising demand for peptide-based drugs. Notably, profitability improved significantly, with EBITDA reaching EUR 25.4 million, marking a sharp margin increase to 7.5% from -1.9% in 2023. This turnaround was attributed to operational enhancements and optimized product offerings.

The company generated EUR 89.4 million in net cash flow from operating activities, a substantial rise from EUR 36.5 million in 2023, as part of its strategy to prepare for future growth. PolyPeptide invested EUR 87.8 million in capital expenditure, 26.1% of its revenue, to expand manufacturing capacity to meet growing customer demand.

Looking forward, PolyPeptide aims to accelerate revenue growth by 10% to 20% in 2025, focusing on scaling up commercial production in its new Belgium facility. The ongoing capacity expansion projects in France and Sweden are on track, supporting the company's mid-term goal of doubling revenue by 2028.